Martine A. Rothblatt Sells 1,272 Shares of United Therapeutics Corp. (UTHR) Stock
United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,272 shares of the stock in a transaction that occurred on Thursday, September 29th. The shares were sold at an average price of $116.94, for a total value of $148,747.68. Following the completion of the sale, the chief executive officer now directly owns 1,412 shares of the company’s stock, valued at $165,119.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
United Therapeutics Corp. (NASDAQ:UTHR) opened at 118.08 on Friday. United Therapeutics Corp. has a 52-week low of $97.52 and a 52-week high of $164.04. The firm has a market cap of $5.13 billion, a price-to-earnings ratio of 5.71 and a beta of 1.46. The firm’s 50 day moving average price is $123.53 and its 200 day moving average price is $115.94.
United Therapeutics Corp. (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 28th. The biotechnology company reported $4.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.22 by $1.33. United Therapeutics Corp. had a return on equity of 49.30% and a net margin of 64.26%. The company had revenue of $412.60 million for the quarter, compared to the consensus estimate of $395.15 million. During the same quarter in the previous year, the business earned $2.55 EPS. United Therapeutics Corp.’s revenue was up 18.8% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corp. will post $15.82 EPS for the current fiscal year.
Several brokerages recently commented on UTHR. Zacks Investment Research cut United Therapeutics Corp. from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 8th. HC Wainwright reissued a “hold” rating on shares of United Therapeutics Corp. in a report on Friday, July 29th. JPMorgan Chase & Co. cut their price objective on United Therapeutics Corp. from $145.00 to $129.00 and set a “neutral” rating for the company in a report on Friday, July 29th. Jefferies Group restated a “hold” rating and issued a $120.00 target price on shares of United Therapeutics Corp. in a research note on Friday, July 29th. Finally, Wedbush restated an “outperform” rating and issued a $229.00 target price on shares of United Therapeutics Corp. in a research note on Thursday, July 28th. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $137.09.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP increased its position in United Therapeutics Corp. by 4.0% in the second quarter. GSA Capital Partners LLP now owns 32,696 shares of the biotechnology company’s stock worth $3,463,000 after buying an additional 1,267 shares during the period. State Street Corp increased its stake in United Therapeutics Corp. by 6.1% in the first quarter. State Street Corp now owns 1,846,710 shares of the biotechnology company’s stock valued at $205,778,000 after buying an additional 105,824 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. increased its stake in United Therapeutics Corp. by 10.9% in the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,540 shares of the biotechnology company’s stock valued at $283,000 after buying an additional 250 shares during the last quarter. Maryland Capital Management increased its stake in United Therapeutics Corp. by 8.7% in the first quarter. Maryland Capital Management now owns 186,457 shares of the biotechnology company’s stock valued at $20,777,000 after buying an additional 14,973 shares during the last quarter. Finally, Spark Investment Management LLC bought a new stake in United Therapeutics Corp. during the first quarter valued at $1,147,000.
United Therapeutics Corp. Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).
Receive News & Stock Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related stocks with our FREE daily email newsletter.